The Menopause Symptom No One Talks About — But Almost Everyone Experiences
Walk into a room of women discussing menopause and hot flashes will dominate the conversation. Sleep problems, mood changes, weight gain — all well-covered territory. But there’s another symptom cluster that affects the majority of postmenopausal women, significantly impacts quality of life, gets progressively worse without treatment, and yet is rarely discussed openly — even between a patient and her gynecologist.
Genitourinary syndrome of menopause (GSM) is the medical term for the changes that occur in the vulva, vagina, and urinary tract as estrogen levels fall. GSM includes vaginal dryness, vaginal itching and burning, pain during intercourse, reduced vaginal lubrication, recurrent urinary tract infections, urinary urgency and frequency, and urinary incontinence. Up to 70 percent of postmenopausal women experience at least some of these symptoms, yet studies consistently show that fewer than a quarter seek medical help for them.
At our gynecology practice in Sugar Land and Missouri City, we want you to know: GSM is not something to normalize, suffer through, or feel embarrassed about. It’s a medical condition with multiple effective treatments. There is no reason to simply endure it.
What Causes GSM
Unlike hot flashes, which often improve over time as the body adapts to lower estrogen levels, GSM is driven by the loss of estrogen’s direct effects on the tissues of the vulva, vagina, and lower urinary tract — tissues that are very estrogen-dependent. Without adequate estrogen, these tissues undergo predictable changes: thinning, loss of elasticity, decreased lubrication, and reduced glycogen content in vaginal cells (which supports healthy vaginal pH and bacterial flora).
The vaginal epithelium (lining) becomes thinner and more fragile. The vaginal walls lose some of their rugae (folds), reducing the ability to expand. Vaginal pH rises, making the environment less hospitable to beneficial Lactobacillus bacteria and more susceptible to bacterial overgrowth and infection. Collagen loss reduces elasticity and can cause the vaginal opening to narrow over time if not treated.
The lower urinary tract — the bladder and urethra — is also estrogen-dependent, which is why urinary symptoms commonly accompany vaginal symptoms. The urethra can become more fragile and prone to irritation, contributing to urinary urgency, frequency, and a higher frequency of urinary tract infections.
How GSM Differs From Hot Flashes
A crucial distinction: unlike vasomotor symptoms, which typically diminish over time as the body adjusts, GSM tends to worsen progressively over the postmenopausal years without treatment. The structural and functional changes in the genitourinary tissues are cumulative. This means that waiting to treat GSM until symptoms become intolerable means starting treatment from a position of more advanced tissue change — and recovery takes longer.
Starting treatment early — even when symptoms are mild — is the most effective strategy. Treatment maintains tissue health and prevents the progressive worsening that untreated GSM produces.
Local (Vaginal) Estrogen: The Gold Standard Treatment
Low-dose vaginal estrogen is considered the most effective treatment for GSM and is the first-line recommendation in the NAMS 2020 GSM Position Statement. It is available in multiple forms: vaginal cream (conjugated estrogen cream or estradiol cream), vaginal tablets (Vagifem, Yuvafem), vaginal suppositories, and a slow-release vaginal ring (Estring) that delivers low-dose estradiol continuously for 90 days.
The critical point about vaginal estrogen is that, used at recommended low doses, systemic absorption is minimal. Blood estrogen levels after vaginal estrogen use remain well within normal postmenopausal range. This means that the cardiac, clot, and breast cancer risks associated with systemic hormone therapy generally do not apply to vaginal estrogen. The NAMS guidelines specifically note that for most women — including most breast cancer survivors who have failed non-hormonal GSM treatments — low-dose vaginal estrogen is considered safe. (Women on aromatase inhibitors for hormone-receptor-positive breast cancer should discuss with their oncologist before starting any vaginal estrogen.)
Non-Estrogen Prescription Options
For women who are not candidates for vaginal estrogen or prefer to avoid it, several alternatives exist. Ospemifene (Osphena) is an oral selective estrogen receptor modulator (SERM) specifically FDA-approved for moderate to severe vaginal dryness and pain with intercourse due to menopause. It acts like estrogen on vaginal tissue without stimulating the breast or uterus. Prasterone (Intrarosa), a vaginal suppository containing dehydroepiandrosterone (DHEA), converts to estrogen and testosterone locally in vaginal cells and is FDA-approved for painful intercourse due to GSM. Both are effective alternatives to vaginal estrogen.
Non-Hormonal Approaches
Vaginal moisturizers — used regularly several times per week regardless of sexual activity — help maintain vaginal moisture and pH. Products containing hyaluronic acid or polycarbophil (such as Replens) have the best evidence for ongoing symptom relief. These are different from lubricants, which provide temporary lubrication for sexual activity but don’t address the underlying tissue changes.
Lubricants (water-based, silicone-based, or oil-based depending on preference and context) are important for managing discomfort during intercourse. Silicon-based lubricants tend to last longer. Oil-based lubricants (coconut oil, etc.) are effective but not compatible with latex condoms.
Regular sexual activity — partnered or solo — increases vaginal blood flow and helps maintain vaginal elasticity. This is not merely anecdotal; pelvic physical therapy, which is available specifically for postmenopausal women, can help address pelvic floor tightness, dyspareunia (painful intercourse), and urinary symptoms with targeted exercises and manual techniques.
Addressing Urinary Symptoms
The urinary symptoms of GSM — urgency, frequency, recurrent UTIs — deserve specific attention and often benefit from targeted treatment in addition to addressing vaginal symptoms. Vaginal estrogen improves the health of the urethral tissue and may reduce the frequency of recurrent UTIs in postmenopausal women. Pelvic floor physical therapy can significantly improve urgency incontinence and frequency. For overactive bladder symptoms, medications including oxybutynin and mirabegron are available.
Recurrent postmenopausal UTIs (three or more per year) are a recognized consequence of GSM and should be evaluated and managed proactively — prophylactic low-dose vaginal estrogen has good evidence for reducing UTI recurrence in postmenopausal women.
The Sexual Health Dimension
Painful intercourse (dyspareunia) due to GSM takes a significant toll on intimate relationships and sexual well-being. Avoiding or delaying sex because of pain is understandable but often accelerates genital atrophy and narrows the vaginal opening further. Effective treatment reverses this cycle. If dyspareunia has been a barrier to intimacy, addressing the underlying GSM can meaningfully restore sexual function and relationship satisfaction.
Don’t let embarrassment keep you from getting effective treatment for these symptoms. Our team in Sugar Land and Missouri City approaches genitourinary health as part of comprehensive care — not as a peripheral or awkward topic. Whatever you’re experiencing, we’re here to help.
